Form EFFECT Aclaris Therapeutics,
Tweet
Share
E-mail| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 7, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Brandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer Therapeutics
- MGI Tech and Shanghai AI Laboratory Unveil ProtoPilot and BioLab Bench, Pioneering Physical AI for Life Sciences
- Beaumont Jewelry Collective Announces Purpose Driven Online Fine Jewelry Platform Curated By Mother And Daughter Gemologists
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
